U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                   FORM 10-QSB

(Mark One)

[x] Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of
1934 for the quarterly period ended December 31, 2001.

[ ]  Transition  report  pursuant to Section 13 or 15(d) of the Exchange act for
the   transition   period   from _____ to _________

Commission File Number:    0-20316
                       --------------
                                  Avitar, Inc.
--------------------------------------------------------------------------------
(Exact name of small business issuer as specified in its charter)

Delaware                                            06-1174053
------------------------------------------------------------------------------
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
incorporation or organization)


65 Dan Road, Canton, Massachusetts                                  02021
-------------------------------------------------------------------------------
(Address of principal executive offices)                         (Zip Code)

                                 (781) 821-2440
 -----------------------------------------------------------------------------
                          (Issuer's telephone number)


(Former  name,  former  address and former  fiscal year,  if changed  since last
report)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. [x]Yes [ ]No

                      APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date:

COMMON STOCK: 42,097,150 AS OF FEBRUARY 8, 2001

Transitional Small Business Disclosure Format
(Check One):               [  ] Yes ;       [x] No



                               Page 1 of 16 pages



                                TABLE OF CONTENTS


                                                                           Page


PART I: FINANCIAL INFORMATION                                                 3


 Item 1 Consolidated Financial Statements
                 Balance Sheet                                                4
                 Statements of Operations                                     5
                 Statement of Stockholders' Equity                            6
                 Statements of Cash Flows                                     7
                 Notes to Consolidated Financial Statements                   8


 Item 2 Management's Discussion and Analysis or Plan of Operation            11



PART II: OTHER INFORMATION                                                   14

 Item 2 Changes in Securities and Use of Proceeds                            15


 Item 6 Exhibits and Reports on Form 8-K                                     15


SIGNATURES                                                                   16
<PAGE>

                          PART I FINANCIAL INFORMATION
<PAGE>


Item 1.     FINANCIAL STATEMENTS

                          Avitar, Inc. and Subsidiaries
                           Consolidated Balance Sheet
                               December 31, 2001
                                   (Unaudited)
------------------------------------------------------------------------------
                                     ASSETS
CURRENT ASSETS:
     Cash and cash equivalents                                       $  587,635
     Accounts receivable                                              1,182,497
     Inventories                                                        441,078
     Prepaid expenses and other                                         113,711
                                                                   -------------
          Total current assets                                        2,324,921

PROPERTY AND EQUIPMENT, net                                             438,020
GOODWILL, net                                                         2,372,049
OTHER ASSETS                                                            138,964
                                                                   -------------
          Total                                                     $ 5,273,954
                                                                   =============

                           LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
     Notes payable                                                    $ 206,866
     Accounts payable                                                 1,722,123
     Accrued expenses                                                   849,942
     Deferred revenue                                                    32,898
     Current portion of long-term debt                                   56,588
                                                                   -------------
          Total current liabilities                                   2,868,417

LONG TERM DEBT, LESS CURRENT PORTION                                     15,828
                                                                   -------------
          Total liabilities                                           2,884,245
                                                                   -------------

COMMITMENTS

STOCKHOLDERS' EQUITY:
     Series A, B, C and D convertible preferred stock,
       $.01 par value; authorized 5,000,000 shares;
       1,978,528 shares issued and outstanding                           19,785
     Common Stock, $.01 par value; authorized
       100,000,000 shares; 40,071,876 shares issued
       and outstanding                                                  400,719
     Additional paid-in capital                                      40,014,002
     Accumulated deficit                                            (37,984,156)
                                                                   -------------
                                                                      2,450,350
     Less preferred stock subscription receivable                       (60,641)
                                                                   -------------
          Total stockholders' equity                                  2,389,709
                                                                   -------------
          Total                                                     $ 5,273,954
                                                                   =============

          See accompanying notes to consolidated financial statements.

<PAGE>
                          Avitar, Inc. and Subsidiaries
                      Consolidated Statements of Operations
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                                                   THREE MONTHS ENDED DECEMBER 31,
                                                                                -----------------------------------------
                                                                                    2001                         2000
                                                                                -------------               -------------

<S>                                                                              <C>                         <C>
SALES                                                                            $ 3,242,414                 $ 1,169,336
                                                                                -------------               -------------

OPERATING EXPENSES
     Cost of sales                                                                 1,637,841                     884,218
     Selling, general and administrative                                           1,508,918                   1,379,999
     Research and development                                                        392,155                     434,713
     Amortization of goodwill                                                         77,498                      70,424
                                                                                -------------               -------------
          Total operating expenses                                                 3,616,412                   2,769,354
                                                                                -------------               -------------

LOSS FROM OPERATIONS                                                                (373,998)                 (1,600,018)
                                                                                -------------               -------------

OTHER INCOME (EXPENSE)
     Interest income                                                                       -                         146
     Interest expense and financing costs                                            (20,575)                     (9,933)
     Other income (expense)                                                           16,167                        (712)
                                                                                -------------               -------------
          Total other expense                                                         (4,408)                    (10,499)
                                                                                -------------               -------------

NET LOSS                                                                          $ (378,406)               $ (1,610,517)
                                                                                =============               =============

BASIC AND DILUTED NET LOSS PER SHARE (Note 5):
     Loss per share before cumulative effect of accounting change                    $ (0.01)                    $ (0.06)
     Cumulative effect of accounting change                                                -                       (0.03)
                                                                                -------------               -------------
     Net loss per share                                                              $ (0.01)                    $ (0.09)
                                                                                =============               =============

WEIGHTED AVERAGE
     NUMBER OF COMMON SHARES OUTSTANDING                                          38,769,464                  30,934,411
                                                                                =============               =============
</TABLE>

          See accompanying notes to consolidated financial statements.

<PAGE>
                          Avitar, Inc. and Subsidiaries
                 Consolidated Statement of Stockholders' Equity
                      Three Months Ended December 31, 2001
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                                                                               Preferred
                                          Preferred Stock         Common Stock                                   Stock
                                        .....................  ....................
                                                                               Additional            Accumulated       Subscription
                                         Shares      Amount     Shares     Amount   paid-in capital    deficit          Receivable
---------------------------------     ------------  ---------  ---------- --------- ---------------   -----------       ----------

<S>                                     <C>          <C>       <C>         <C>       <C>             <C>                <C>
Balance at September 30, 2001           2,203,690    $22,036   36,564,342  $365,643  $39,338,443     ($37,592,117)      ($60,641)

Sale of common stock and warrants               -          -     974,390      9,744      651,257                -              -

Exercise of stock options and warrants          -          -     464,664      4,647       29,103                -              -

Conversion of Series B and Series C
 preferred stock into common stoc(        226,557)    (2,265)  2,068,480     20,685      (18,420)               -              -

Payment of preferred stock dividend,
  Series B preferred stock                  1,395         14           -          -       13,619          (13,633)             -

Net loss                                        -          -           -          -            -         (378,406)             -
-----------------------------------     ----------  ---------  ----------  --------- ------------      -----------      ----------

Balance at December 31, 2001            1,978,528    $19,785   40,071,876  $400,719  $40,014,002     ($37,984,156)      ($60,641)
-----------------------------------     ----------  ---------  ----------  --------- ------------      -----------      ----------
</TABLE>

          See accompanying notes to consolidated financial statements.
<PAGE>
                          Avitar, Inc. and Subsidiaries
                      Consolidated Statements of Cash Flows
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                                     THREE MONTHS ENDED DECEMBER 31,
                                                                       2001                2000
                                                                  --------------     --------------
CASH FLOWS FROM OPERATING ACTIVITIES:
<S>                                                                 <C>               <C>
 Net loss                                                           ($378,406)        ($1,610,517)
 Adjustments to reconcile net loss to net cash used in
  operating activities:
    Depreciation and amortization                                      47,020              38,336
    Amortization of goodwill                                           77,498              70,424
    Gain from sale of equity investment                               (13,391)
    Changes in operating assets and liabilities:
     Accounts receivable                                              134,261             (38,722)
     Inventories                                                     (196,720)            222,123
     Prepaid expenses and other current assets                         46,611              49,535
     Other assets                                                       9,592              97,550
     Accounts payable and accrued expenses                            305,847             108,458
     Deferred revenue                                                (352,102)                  -
                                                                  -------------      --------------
          Net cash used in operating activities                      (319,790)         (1,062,813)
                                                                  -------------      --------------

CASH FLOWS FROM INVESTING ACTIVITIES:

 Purchases of property and equipment                                  (41,286)            (12,527)
 Proceeds from sale of equity investment                               24,391                   -

                                                                   ------------      --------------

           Net cash used in investing activities                      (16,895)            (12,527)
                                                                   ------------      --------------

CASH FLOWS FROM FINANCING ACTIVITIES:

 Repayment of notes payable and long-term debt                        (50,840)           (21,777)
 Sales of common stock, preferred stock and warrants                  661,001           1,034,700
 Stock subscription receivable                                         35,000              42,228
 Exercise of stock options and warrants                                33,750                   -
                                                                   ------------      -------------

          Net cash provided by financing activities                   678,911           1,055,151
                                                                   ------------      -------------

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                  342,226             (20,189)

CASH AND CASH EQUIVALENTS, beginning of the period                    245,409              82,313
                                                                   ------------      -------------

CASH AND CASH EQUIVALENTS, end of the period                         $587,635             $62,124
                                                                   ============      =============

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
 Cash paid during period:
   Income taxes                                                       $ 5,308             $     -
   Interest                                                           $ 7,302             $ 9,759

</TABLE>

          See accompanying notes to consolidated financial statements.
<PAGE>
                          AVITAR, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (UNAUDITED)
================================================================================

1.   BASIS OF PRESENTATION

     Avitar,  Inc.  ("Avitar"  or  the  "Company"),   through  its  wholly-owned
subsidiaries,  Avitar  Technologies  Inc.  ("ATI"),  United  States Drug Testing
Laboratories,   Inc.  ("USDTL")  and  BJR  Security,  Inc.  designs,   develops,
manufactures, markets and provides diagnostic test products and services as well
as contraband detection and education services.  Avitar sells these products and
services to large medical supply companies,  employers, diagnostic distributors,
schools and governmental agencies. During Fiscal Year 2001 and the first quarter
of Fiscal Year 2002,  the Company  continued  the  development  and marketing of
ORALscreen(TM),  innovative  point of care oral fluid  drugs of abuse tests that
use the Company's foam as the means for collecting the oral fluid sample.

     The accompanying consolidated financial statements of the Company have been
prepared in accordance with generally accepted accounting principles for interim
financial  information,  the  instructions  to Form  10-QSB and  Regulation  S-B
(including  Item 310(b)  thereof).  Accordingly,  they do not include all of the
information and footnotes required by generally accepted  accounting  principles
for complete financial  statements.  In the opinion of the Company's management,
all  adjustments  (consisting  only of  normal  recurring  accruals)  considered
necessary for a fair presentation have been included.  Operating results for the
three-month period ended December 31, 2001 are not necessarily indicative of the
results that may be expected for the full fiscal year ending September 30, 2002.
The accompanying consolidated financial statements should be read in conjunction
with the audited  financial  statements of the Company for the fiscal year ended
September 30, 2001.

     The Company's  consolidated financial statements have been presented on the
basis that it is a going concern,  which  contemplates the realization of assets
and the  satisfaction  of  liabilities  in the normal  course of  business.  The
Company has suffered  recurring losses from operations and has a working capital
deficit as of December  31, 2001 of  $543,496.  The Company  raised net proceeds
aggregating approximately $5,288,000 during fiscal year ended September 30, 2001
from the sale of stock and the  exercise  of options  and  warrants.  During the
three months ended December 31, 2001, the Company raised approximately  $695,000
from the sale of common  stock and  warrants  and the  exercise  of options  and
warrants. Based upon cash flow projections, the Company believes the anticipated
cash flow from  operations  and proceeds from future equity  financings  will be
sufficient to finance the Company's operating needs until the operations achieve
profitability.  There  can be no  assurances  that  forecasted  results  will be
achieved or that additional financing will be obtained. The financial statements
do not include any adjustments relating to the recoverability and classification
of asset amounts or the amounts and  classification of liabilities that might be
necessary should the Company be unable to continue as a going concern.






2.   INVENTORIES

At December 31, 2001, inventories consist of the following:

 Raw Materials                                          $131,521
 Work-in-Process                                          83,712
 Finished Goods                                          225,845
                                                       ---------
    Total                                               $441,078
                                                        ========

3.   MAJOR CUSTOMERS

 Customers in excess of 10% of total sales are:

                                           Three Months Ended December 31,
                                           -------------------------------
                                              2001                  2000
                                           -----------         -------------

    Customer A                              $      *             $125,948
    Customer B                             1,590,820                    *

               *Customer was not in excess of 10% of total sales.

4.   COMMON AND PREFERRED STOCK

     During the quarter ended December 31, 2001, the Company sold 974,390 shares
of the Company's common stock and received  proceeds of approximately $ 661,000.
In  connection  with the sale of the common  stock,  the  Company  issued to the
holders of the common stock warrants to purchase 974,390 shares of the Company's
common stock at exercise prices of $.68 to $1.60 per share which expire in three
years.  Also  during the first  quarter of Fiscal  2002,  the  Company  received
approximately  $34,000 from the exercise of warrants to purchase  464,664 shares
of the  Company's  common stock.  For the three months ended  December 31, 2001,
holders of Series B and Series C convertible  preferred stock converted  226,557
shares of preferred stock into 2,068,480 shares of the Company's common stock.

     Preferred  stock  dividends  related to the Series B convertible  preferred
stock for the three months ended  December 31, 2001  amounted to $13,633.  As of
December  31,  2001,  the total amount of unpaid and  undeclared  dividends  was
$325,463.


5.  EARNINGS PER SHARE

The following data show the amounts used in computing earnings per share:

                                                     2001                2000
                                               --------------      -------------
  Net loss                                     $(   378,406)        $(1,610,517)
  Less:
    Preferred Stock Dividends                  (     93,616)       (     95,044)
                                               -------------       -------------


  Loss available to common
    stockholders  used in basic and
    diluted EPS before cumulative
    accounting change                          (    472,022)         (1,705,561)

  Cumulative effect of change in
     accounting for original discount
     related to prior years' preferred
     stock issuances                            (         -)         (1,078,205)
                                              --------------        ------------

  Net loss available to common
     Shareholders used in basic and
          diluted EPS                       $(      472,022)        $(2,783,766)
                                             ================     ==============

  Weighted average number of
     common shares outstanding                    38,769,464          30,934,411
                                             ================     ==============



6.  SUBSEQUENT EVENTS

     Since  December 31, 2001 the Company sold 935,694  shares of the  Company's
common stock and received proceeds of approximately $636,000. In connection with
the sale of the common  stock,  the Company  issued to the holders of the common
stock  warrants to purchase  935,294  shares of the  Company's  common  stock at
exercise  prices of $.85 per share which expire in 5 years.  From January 1,2002
through February 8, 2002, holders of Series B and Series C convertible preferred
stock converted  170,685 shares of preferred stock into 1,034,755  shares of the
Company's common stock.



ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.
---------------------------------------------------------------------------

     The following  discussion and analysis  should be read in conjunction  with
the Company's  consolidated financial statements and the notes thereto appearing
elsewhere in this report.

RESULTS OF OPERATIONS

Revenues

     Sales for the three months ended December 31, 2001 increased  $2,073,078 or
approximately 177 %, to $3,242,414 from $1,169,336 for the corresponding  period
of the prior  year.  The change for the three  months  ended  December  31, 2001
primarily  reflects the increase in sales of its  OralScreen(TM)  products which
included an increase in sales to one major customer of approximately $1,780,000.

Operating Expenses

     Cost  of  sales  for  the  three  months  ended   December  31,  2001  were
approximately 51% of sales compared to the cost of sales of approximately 76% of
sales for the three months ended  December 31,  2000.  The  improvement  for the
first  quarter  of Fiscal  2002 is mainly the  result of the  increase  in sales
described above and the shift in the product mix to ORALscreen.

     Selling,  general and  administrative  expenses  for the three months ended
December 31,2001  increased $ 128,919,  or approximately  9%, to $1,508,918 from
$1,379,999 for the corresponding  period of the prior year. The increase for the
three-month  period ended  December  31, 2001  continued to reflect the expanded
sales,  marketing  and  administrative  efforts  associated  with the  Company's
OralScreen  and  HAIRscreen  products and services and BJR's selling and general
administrative expenses of approximately $64,000.

     Expenses for research and  development  for the three months ended December
31, 2001 amounted to $392,155 compared to $434,713 for the corresponding  period
of the prior year.  The decrease of $42,558,  or  approximately  10%,  primarily
reflects some minor adjustments to the research and development  process for the
Company's OralScreen products.

     For the three months ended December 31, 2001,  amortization of goodwill was
$77,498  compared to $70,424 for the three months ended  December 31, 2000.  The
increase  is a  result  of the  amortization  of  goodwill  associated  with the
acquisition of BRJ which took place on March 1, 2001.

     Other Income and Expense

     No interest  income was  recorded for the quarter  ended  December 31, 2001
compared to $146 for the same period of the prior year.  The decrease  primarily
reflects the reduction in interest earned on cash management accounts.

     Interest  expense and  financing  costs were  $20,575 for the three  months
ended  December  31, 2001  compared to $9,933  incurred  during the three months
ended December 31, 2000. The increase  resulted  primarily from interest expense
on accounts receivable financing and loans from private parties.

     For the three months ended  December  31,  2001,  other income  amounted to
$16,167  compared to other  expense of $712 for the three months ended  December
31, 2000. This change mainly reflects the income from the sale of a small equity
investment held by the Company.

         Net Loss

     Primarily as a result of the factors described above, the Company had a net
loss of $378,406 for the three months  ended  December 31, 2001,  as compared to
net loss of $1,610,517  for the three months ended  December 31, 2000.  The loss
per  share  was $.01 per basic and  diluted  share  for the three  months  ended
December 31, 2001. The loss per share before the cumulative effect of the change
in accounting  included in the three months ended  December 31 2000 was $.06 per
basic and diluted  share and the loss per share after the  cumulative  effect of
the accounting  change was $.09 per basic and diluted share for the three months
ended December 31, 2000.

FINANCIAL CONDITION AND LIQUIDITY

     At December 31, 2001 and September 30, 2001 the Company had working capital
deficiencies  of  $543,496  and  $958,293,   respectively,  and  cash  and  cash
equivalents  of $587,635 and $245,409  respectively.  Net cash used in operating
activities  during the three months ended December 31, 2001 amounted to $319,790
resulting  primarily  from a net loss of  $378,406,  a gain  from the sale on an
equity  investment,  an increase in  inventories  of $196,720  and a decrease in
deferred income of $352,102;  partially  offset by depreciation and amortization
of  $47,020,  amortization  of  goodwill  of  $77,498,  a decrease  in  accounts
receivable of $134,261,  a decrease in prepaid expenses and other current assets
of  $46,611,  a decrease  in other  assets of $9,592 and  increases  in accounts
payable and accrued  expenses of $305,847.  Net cash  provided by financing  and
investing activities during the three months ended December 31, 2001 amounted to
$662,016  which  included  proceeds  from the sale of an  equity  investment  of
$24,391,  proceeds  from the sale of common stock and  warrants of  $661,001,  a
decrease  in stock  subscription  receivable  of $35,000 and  proceeds  from the
exercise  of  warrants  of  $33,750;  offset in part by the  repayment  of notes
payable and long term debt of $50,840 and purchases of property and equipment of
$41,286.

     Since  October  2001,  the  Company  received   proceeds  of  approximately
$1,297,000 from the sale of 1,909,684  shares of the Company's  common stock and
warrants to purchase  1,909,684 shares of the Company's common stock at exercise
prices of $.68 -$1.60 per share for a period of three to five years. The Company
plans  to  raise  up to  $10,000,000  from  the  sales  of  equity  and/or  debt
securities.  The Company  plans to use the  proceeds  from these  financings  to
provide working capital and capital equipment funding to operate the Company, to
expand the Company's business, to further develop and enhance the ORALscreen and
HAIRscreen drug screening systems and to pursue the development of in-vitro oral
fluid diagnostic testing products. However, there can be no assurance that these
financings will be achieved.

     For the balance of fiscal year 2002,  the Company's cash  requirements  are
expected to include  primarily the funding of operating  losses,  the payment of
outstanding  accounts  payable,  the  repayment of certain  notes  payable,  the
funding  of  operating  capital  to grow the  Company's  drugs of abuse  testing
products and services, and the continued funding for the development of in-vitro
oral fluid diagnostic testing products.

     Operating  revenues of the Company  (exclusive  of revenues  from BJR) grew
significantly  in the first  quarter  of Fiscal  2002 and are  expected  to grow
during the remainder of Fiscal 2002 as the Company  expands its shipments of new
and enhanced  ORALscreen products and grows the business of USDTL and BJR. Based
on current sales,  expense and cash flow projections,  the Company believes that
the current level of cash and cash equivalents on hand and most  importantly,  a
portion of the anticipated net proceeds from the financing mentioned above would
be sufficient to fund operations until the Company achieves profitability. There
can be no  assurance  that  the  Company  will  consummate  the  above-mentioned
financing,  or  that  any or all of the  net  proceeds  sought  thereby  will be
obtained.  Once  the  Company  achieves  profitability,   the  longer-term  cash
requirements  of the  Company to fund  operating  activities,  purchase  capital
equipment, expand the existing business and develop new products are expected to
be met by the  anticipated  cash  flow from  operations  and  proceeds  from the
financings  described  above.  However,  because there can be no assurances that
sales will  materialize  as  forecasted,  management  will  continue  to closely
monitor  and  attempt to  control  costs at the  Company  and will  continue  to
actively seek the needed additional capital.

     As a result of the Company's  recurring  losses from operations and working
capital  deficit,  the report of its independent  certified  public  accountants
relating to the financial  statements  for Fiscal 2001  contains an  explanatory
paragraph stating substantial doubt about the Company's ability to continue as a
going concern. Such report states that the ultimate outcome of this matter could
not be determined as the date of such report  (November 20, 2001). The Company's
plans to address  the  situation  are  presented  above.  However,  there are no
assurances that these endeavors will be successful or sufficient.

FORWARD-LOOKING STATEMENTS AND ASSOCIATED RISKS

     Except for the historical  information  contained  herein,  the matters set
forth herein are "forward-looking  statements" within the meaning of Section 27A
of the  Securities Act of 1933,  Section 21E of the  Securities  Exchange Act of
1934 and the Private  Securities  Litigation  Reform Act of 1995. We intend that
such forward-looking statements be subject to the safe harbors created thereby.

     Such   forward-looking   statements   involve  known  and  unknown   risks,
uncertainties and other factors which may cause our actual results,  performance
or achievements to be materially different from any future results,  performance
or achievement  expressed or implied by such  forward-looking  statements.  Such
factors include, but are not limited to the following: product demand and market
acceptance  risks,  the  effect of  economic  conditions,  results of pending or
future  litigation,  the impact of  competitive  products and  pricing,  product
development  and  commercialization,   technological  difficulties,   government
regulatory  environment  and  actions,  trade  environment,  capacity and supply
constraints or difficulties,  the result of financing efforts,  actual purchases
under agreements and the effect of the Company's accounting policies.


                            PART II OTHER INFORMATION



ITEM 2. CHANGE IN SECURITIES AND USE OF PROCEEDS

     During the quarter  ended  December 31,  2001,  the Company sold to private
investors  974,390  shares  of the  Company's  common  stock and  received  cash
proceeds of approximately  $661,000.  In connection with the sale of this common
stock,  the  Company  issued to the  holders of the  common  stock  warrants  to
purchase  974,390  shares of the Company's  common stock at an exercise price of
$.68 to $ 1.60  per  share  which  expire  in three  years.  The  exemption  for
registration  of these  securities is based upon Section 4(2) of the  Securities
Act.

ITEM 6.           EXHIBITS AND REPORTS ON FORM 8-K

(a)  Exhibits:

       None


(b)      Reports on Form 8-K:

         None

<PAGE>

                                   SIGNATURES

In accordance with the  requirements of the Exchange Act, the Registrant  caused
this  report to be  signed on its  behalf  by the  undersigned,  thereunto  duly
authorized.


                                  AVITAR, INC.
                                  (Registrant)




Dated:  February 14, 2002         /S/ Peter P. Phildius
                                  -----------------------------------
                                  Peter P. Phildius
                                  Chairman and Chief
                                  Executive Officer
                                  (Principal Executive Officer)



Dated:  February 14, 2002         /S/ J.C. Leatherman, Jr.
                                  ---------------------------
                                  J.C. Leatherman, Jr.
                                  Chief Financial Officer
                                  (Principal Accounting and
                                  Financial Officer)